These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28301423)

  • 41. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course.
    Raffi F; Le Moing V; Assuied A; Habak S; Spire B; Cazanave C; Billaud E; Dellamonica P; Ferry T; Fagard C; Leport C;
    J Antimicrob Chemother; 2017 Jan; 72(1):240-245. PubMed ID: 27629069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of deworming on disease progression markers in HIV-1-infected pregnant women on antiretroviral therapy: a longitudinal observational study from Rwanda.
    Ivan E; Crowther NJ; Mutimura E; Rucogoza A; Janssen S; Njunwa KK; Grobusch MP
    Clin Infect Dis; 2015 Jan; 60(1):135-42. PubMed ID: 25210019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells.
    Ke R; Lewin SR; Elliott JH; Perelson AS
    PLoS Pathog; 2015 Oct; 11(10):e1005237. PubMed ID: 26496627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Trends in Immunity and Adverse Drug Reactions Among People Newly Diagnosed With HIV].
    Lin YC; Lai YY; Liu HY; Chen YC; Liu LF; Ko NY
    Hu Li Za Zhi; 2020 Feb; 67(1):55-65. PubMed ID: 31960397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals.
    Ho YC; Laird GM; Siliciano RF
    Proc Natl Acad Sci U S A; 2014 May; 111(19):6860-1. PubMed ID: 24799684
    [No Abstract]   [Full Text] [Related]  

  • 46. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.
    Archin NM; Bateson R; Tripathy MK; Crooks AM; Yang KH; Dahl NP; Kearney MF; Anderson EM; Coffin JM; Strain MC; Richman DD; Robertson KR; Kashuba AD; Bosch RJ; Hazuda DJ; Kuruc JD; Eron JJ; Margolis DM
    J Infect Dis; 2014 Sep; 210(5):728-35. PubMed ID: 24620025
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of HIV infection and antiretroviral therapy initiation on genome-wide DNA methylation patterns.
    Esteban-Cantos A; Rodríguez-Centeno J; Silla JC; Barruz P; Sánchez-Cabo F; Saiz-Medrano G; Nevado J; Mena-Garay B; Jiménez-González M; de Miguel R; Bernardino JI; Montejano R; Cadiñanos J; Marcelo C; Gutiérrez-García L; Martínez-Martín P; Wallet C; Raffi F; Rodés B; Arribas JR;
    EBioMedicine; 2023 Feb; 88():104434. PubMed ID: 36640455
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brief Report: Impact of ART Classes on the Increasing Risk of Cerebral Small-Vessel Disease in Middle-Aged, Well-Controlled, cART-Treated, HIV-Infected Individuals.
    Januel E; Godin O; Moulignier A; Lescure FX; Savatovsky J; Lamirel C; Valin N; Tubiana R; Canestri A; Roux P; Sadik JC; Salomon L; Katlama C; Yazdanpanah Y; Pialoux G; Girard PM; Costagliola D; Assoumou L;
    J Acquir Immune Defic Syndr; 2019 Aug; 81(5):547-551. PubMed ID: 31107300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal.
    McMahon JH; Evans VA; Lau JSY; Symons J; Zerbato JM; Chang J; Solomon A; Tennakoon S; Dantanarayana A; Hagenauer M; Lee S; Palmer S; Fisher K; Bumpus N; Heck CJS; Burger D; Wu G; Zuck P; Howell BJ; Zetterberg HH; Blennow K; Gisslen M; Rasmussen TA; Lewin SR
    AIDS; 2022 Jan; 36(1):75-82. PubMed ID: 34586085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy.
    McMahon DK; Zheng L; Cyktor JC; Aga E; Macatangay BJ; Godfrey C; Para M; Mitsuyasu RT; Hesselgesser J; Dragavon J; Dobrowolski C; Karn J; Acosta EP; Gandhi RT; Mellors JW
    J Infect Dis; 2021 Aug; 224(4):648-656. PubMed ID: 34398236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of HIV infection in patients with cancer receiving chemotherapy.
    Torres HA; Mulanovich V
    Clin Infect Dis; 2014 Jul; 59(1):106-14. PubMed ID: 24642555
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiretroviral therapy: need for a long-term view.
    Maniar JK
    Indian J Dermatol Venereol Leprol; 2006; 72(6):401-4. PubMed ID: 17179612
    [No Abstract]   [Full Text] [Related]  

  • 53. Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1.
    Chang CC; Naranbhai V; Stern J; Roche M; Dantanarayana A; Ke R; Tennakoon S; Solomon A; Hoh R; Hartogensis W; Hecht FM; Sikaris K; Price DJ; Elliott JH; Deeks SG; Churchill M; Cameron PU; Hengartner N; Perelson AS; Lewin SR
    AIDS; 2018 Sep; 32(15):2119-2128. PubMed ID: 30005017
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Short-term effectiveness and safety of third-line antiretroviral regimens among patients in Western India.
    Pujari SN; Makane A; Lodha A; Bele V; Joshi K
    J Acquir Immune Defic Syndr; 2014 Feb; 65(2):e82-4. PubMed ID: 24442229
    [No Abstract]   [Full Text] [Related]  

  • 55. Anticancer drug shows promise against lupus.
    Foubister V
    Drug Discov Today; 2003 Apr; 8(8):333-4. PubMed ID: 12681930
    [No Abstract]   [Full Text] [Related]  

  • 56. Cancer risk in HIV-infected patients: elite controllers are also concerned.
    Poizot-Martin I; Laroche H; Cano CE; Nicolino-Brunet C; Zaegel-Faucher O; Bregigeon S; Tamalet C; Dignat-George F
    AIDS; 2018 Mar; 32(5):673-675. PubMed ID: 29494425
    [No Abstract]   [Full Text] [Related]  

  • 57. Body-drug assemblages: theorizing the experience of side effects in the context of HIV treatment.
    Gagnon M; Holmes D
    Nurs Philos; 2016 Oct; 17(4):250-61. PubMed ID: 27435229
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comment on: "Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study from Ethiopia".
    Cotton M; Nicol S
    Drug Saf; 2015 Oct; 38(10):931. PubMed ID: 26242617
    [No Abstract]   [Full Text] [Related]  

  • 59. Surrogate markers in oncology practice and anticancer drug development: lessons learned from antiretroviral therapy?
    Remick SC
    Cancer Invest; 2004; 22(1):164-8. PubMed ID: 15069775
    [No Abstract]   [Full Text] [Related]  

  • 60. Authors' Reply to Cotton and Nicol's Comment on "Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study from Ethiopia".
    Bezabhe WM; Bereznicki LR; Chalmers L; Gee P; Kassie DM; Bimirew MA; Peterson GM
    Drug Saf; 2015 Oct; 38(10):933. PubMed ID: 26242618
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.